Compare · ATRC vs SYK
ATRC vs SYK
Side-by-side comparison of AtriCure Inc. (ATRC) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATRC and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 38.3x ATRC ($2.94B).
- Over the past year, ATRC is up 51.1% and SYK is down 21.3% - ATRC leads by 72.4 points.
- SYK has been more active in the news (8 items in the past 4 weeks vs 2 for ATRC).
- SYK has more recent analyst coverage (25 ratings vs 14 for ATRC).
- Company
- AtriCure Inc.
- Stryker Corporation
- Price
- $56.12-2.84%
- $294.69+0.46%
- Market cap
- $2.94B
- $112.48B
- 1M return
- -5.01%
- +5.16%
- 1Y return
- +51.06%
- -21.34%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- News (4w)
- 2
- 8
- Recent ratings
- 14
- 25
AtriCure Inc.
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest ATRC
- AtriCure to Announce Third Quarter 2026 Financial Results
- Chief Technical Officer Privitera Salvatore sold $271,140 worth of shares (4,519 units at $60.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 142,745 units (SEC Form 4)
- Director Groves Regina E sold $288,071 worth of shares (5,313 units at $54.22), decreasing direct ownership by 13% to 34,546 units (SEC Form 4)
- Chief Technical Officer Privitera Salvatore sold $201,135 worth of shares (3,657 units at $55.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 147,264 units (SEC Form 4)
- Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
- Chief Technical Officer Privitera Salvatore sold $407,558 worth of shares (7,763 units at $52.50) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 150,921 units (SEC Form 4)
- Chief Legal Officer Dahlquist Karl S. sold $458,099 worth of shares (9,370 units at $48.89), decreasing direct ownership by 10% to 87,319 units (SEC Form 4)
- AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by AtriCure Inc.
- Director Prange Karen sold $138,283 worth of shares (3,564 units at $38.80), decreasing direct ownership by 14% to 22,809 units (SEC Form 4)
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)